Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta‐analysis.
Abstract: Background and Aims: There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a γ‐aminobutyric acid B (GABA‐B) agonist which is used increasingly as an off‐label treatment. A meta‐analysis of randomized controlled trials (RCTs) was conducted to...
| Publicado en: | Addiction Vol. 113; no. 8; pp. 1396 - 1407 |
|---|---|
| Autores principales: | , |
| Formato: | research systematic review tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Aug2018
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=130671144&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 130671144 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09652140 AIO jtl: Addiction issn: 09652140 maglogo: Y pubinfo: dt: Aug2018 vid: 113 iid: 8 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 130671144 130671144 130671144 10.1111/add.14191 130671144 ppf: 1396 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Baclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta‐analysis. aug: au: Rose, Abigail K. Jones, Andrew affil: Psychological Sciences, University of Liverpool, Liverpool, UK sug: subj: Baclofen Therapeutic Use Affect Prevention and Control Drinking Behavior Prevention and Control Alcohol Drinking Prevention and Control Craving Prevention and Control Depression Prevention and Control Anxiety Prevention and Control Treatment Outcomes Human Systematic Review Meta Analysis Outcome Assessment Intention Odds Ratio Effect Size Confidence Intervals Substance Use Disorders Drug Therapy ab: Abstract: Background and Aims: There are a limited number of pharmacotherapies licensed for alcohol use disorders (AUDs). Baclofen is a γ‐aminobutyric acid B (GABA‐B) agonist which is used increasingly as an off‐label treatment. A meta‐analysis of randomized controlled trials (RCTs) was conducted to determine the efficacy of baclofen in reducing drinking behaviour, craving, depression and anxiety compared with placebo. Methods: Random‐effects meta‐analyses were computed on outcome data from 12 RCTs comparing baclofen with placebo. Included RCTs provided data on at least one of the primary outcome measures (drinking‐related: heavy drinking days, abstinent days, abstinence rates) or secondary outcome measures (craving, anxiety, depression). Results: Baclofen had a significant effect on abstinence rates when using intention‐to‐treat analysis [total n baclofen = 307, total n control = 283: odds ratio (OR) = 2.67, 95% confidence interval (CI) = 1.03, 6.93; Z = 2.01, P = 0.04, I2 = 76%, number needed to treat = 8]. No other significant effects of treatment efficacy [e.g. heavy drinking days: standardized mean differences (SMD) = −0.26, 95% CI = –0.68, 0.15; Z = 1.24, P = 0.21, I2 = 95%] or mechanism of action (e.g. craving: SMD = −0.13, 95% CI = −0.36, 0.09; Z = 1.18, P = 0.24, I2 = 87%) were observed. There was substantial heterogeneity in effect sizes across each analysis. Conclusions: As a treatment for alcohol use disorders, baclofen is associated with higher rates of abstinence than placebo. However, there is no superior effect of baclofen on increasing number of abstinent days, or decreasing heavy drinking, craving, anxiety or depression. These results suggest that the current increasing use of baclofen as a treatment for alcohol use disorders is premature. pubtype: Academic Journal doctype: meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|